BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bloxiverz neostigmine methylsulfate regulatory update

FDA approved an NDA for Bloxiverz neostigmine methylsulfate from Flamel to reverse the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch the

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >